Active Ingredient: rivaroxaban
Strength: 2.5 mg, 10 mg, 15 mg, and 20 mg
Dosage Form: Tablets
Mechanism of Action: Factor Xa inhibitors
First Approval: US (1 Jul 2011), EU (30 Sep 2008)
Revenue Analysis of Xarelto1
Xarelto has been an important driver of the revenue generated from the cardiovascular portfolio of Janssen. The blood thinner showed an increase of 4%…
